Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclo(Prolylglycyl) SCHEMBL4247464 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL30768150 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL21736594 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| Cyclo(Prolylglycyl) SCHEMBL3016264 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL21736595 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL1189351 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3519704 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3519708 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL17516644 | 0.93 | KDM4E (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL464685 | 0.93 | KDM4E (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| CN-101087610-A | Arylpiperazine derivatives and their use as 5-HT1AUse of receptor ligands | SCHWARZ PHARMA S L (ES) | 2007-12-12 | — | — | CN | disclosed |
| US-7304064-B2 | 1-[(indol-3-yl)carbonyl]piperazine derivatives | N.V. ORGANON (NL) | 2007-12-04 | — | — | US | disclosed |
| EP-1549637-B1 | 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES | ORGANON NV (NL) | 2007-05-02 | — | — | EP | disclosed |
| EP-1674103-A1 | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands | Cepa Schwarz Pharma s.l. (ES) | 2006-06-28 | — | — | EP | disclosed |
| US-20050250760-A1 | 1-[(Indol-3-yl)carbonyl]piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| EP-1549637-A1 | 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES | Akzo Nobel N.V. (NL) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004000832-A1 | 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250760-A1 | 1-[(Indol-3-yl)carbonyl]piperazine derivatives | IDO1, OPRL1, OPRK1 | ALDH1A1 689/4885KDM4E 1502/4885MAPT 2304/4885 |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | ALDH1A1 671/4885KDM4E 3602/4885MAPT 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.